SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present three studies that demonstrate the value of the Prolaris test for physicians and their patients at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La.
Key presentations will showcase a new "active surveillance threshold" for men with localized prostate cancer based on the Prolaris test score, and the final results from PROCEDE 1000, which is the largest prospective clinical utility study to measure the impact of the Prolaris test on the treatment of men with localized prostate cancer. Abstracts of the Company's presentations will be available at: www.aua2015.org/abstracts/.
"We are very excited about our presentations at AUA. The results show how the Prolaris test is helping physicians assess the aggressiveness of prostate cancer and more importantly, personalize treatment plans for their patients to achieve better care," said Michael Brawer, M.D., vice president of Medical Affairs, Myriad. "The addition of a validated active surveillance threshold based upon disease-specific mortality provides a unique and definitive tool for physicians and patients to personalize treatment plans."
The data being highlighted at AUA 2015 include:
Podium Presentation
Title: Significant reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients in a large prospective registry (PD32-11).
Podium Presenter: Neal Shore, M.D.
Date: Sunday, May 17, 3:30 p.m. to 5:30 p.m. CT
Room: 215-216
Poster Presentations
Title: Patient AUA risk classification based on combined clinical cell cycle risk (CCR) score (MP1-08).
Poster Presenter: Jack Cuzick, Ph.D.
Date: Friday, May 15, 10:30 a.m. to 12:30 p.m. CT
Room: 220-221
Title: Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer (MP1-10).
Poster Presenter: Jack Cuzick, Ph.D.
Date: Friday, May 15, 10:30 a.m. to 12:30 p.m. CT
Room: 220-221
About Prolaris®
Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy. For more information visit: www.prolaris.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad is focused on strategic initiatives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, and expand internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the presentation of new clinical data on Prolaris at the AUA 2015 meeting; the ability of Prolaris to predict outcomes in prostate cancer patients and significantly improve treatment recommendations for patients or improve care; the ability of Prolaris to set a new standard of care for prognostic genetic testing in men with localized prostate cancer; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing to new testing services, including unexpected costs and delays; risks related to decisions or changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of in our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.